The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.
The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.
Mycoplasma hyopneumoniae (M. hyopneumoniae) infections continue to result in significant respiratory challenges in the swine industry worldwide. Vaccination for M. hyopneumoniae is commonly utilized, as reduction in bacterial loads and clinical severity in vaccinated pigs have been shown. However, the effect of M. hyopneumoniae vaccination on transmission across different pig populations has been minimally investigated.
Don’t miss any news on PRRS disease control Subscribe now to PRRS.com newsletter
After the evaluation of the trial the farm started to use Ingelvac® PRRS MLV in sows (mass vaccination of all breeding animals every 3 month) and pigs (vaccination at 10 days of age) as a tool to control PRRS
Vaccination did not prevent infection, but reduced the impact of clinical disease and prevented hyperpyrexia associated mortality.
Porcine reproductive and respiratory syndrome virus (PRRSV) causes significant reproductive losses inthe sow herd and respiratory disease in growing pigs. The virus belongs to the family Arteriviridae and there are two major genotypes. Type 1 is represented by Lelystad virus, the European prototype virus,and Type 2 is represented by the North American prototype virus, VR-2332. Depending on husbandry, immune status of the herd, and virulence of the isolate, the severity of disease and magnitude of economic loss can be variable. Vaccine use is not always successful indicating a lack of cross-protection between vaccine strains and circulating wild-type viruses. To date, there is no clear method to demonstrate if a vaccine confers protection against a specific isolate except for empirical animal studies.
In this control case, after confirming PRRS infection, the use of Ingelvac®PRRS MLV proved to be effective in reducing both morbidity and post-weaning mortality as well as days to market